English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsOptocircuitsindia

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to
    • Pharma cos likely to post 21% EBITDA growth in Q4: MOST

      Pharma cos likely to post 21% EBITDA growth in Q4: MOST

      Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

    • To ease out working capital woes via rejig: Opto Circuits

      To ease out working capital woes via rejig: Opto Circuits

      Opto Circuits posted a net profit decline of 9 percent. In an interview to CNBC-TV18, Vinod Ramnani, CMD, Opto Circuits said that there are working capital problems and the company is looking at restructuring to alleviate the problem.

    • See pharma sector's Q3 topline to grow 22%: Motilal Oswal

      See pharma sector's Q3 topline to grow 22%: Motilal Oswal

      Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

    • Eyeing better margins in H2FY13: Opto Circuit

      Eyeing better margins in H2FY13: Opto Circuit

      V Bhaskar, Director of Opto Circuits said the company's invasive as well as non-invasive segments have grown well in Q2. Going ahead, he is hopeful of improving margins in the second half of the year.

    • Expect 20% revenue growth in FY13: Opto Circuits

      Expect 20% revenue growth in FY13: Opto Circuits

      In an interview to CNBC-TV18, V Bhaskar, head of finance of Opto Circuits says, he expects 20% revenue growth in FY13.

    • Opto Circuits Q4 PAT seen up 3% at Rs 114 cr

      Opto Circuits Q4 PAT seen up 3% at Rs 114 cr

      Opto Circuits is expected to report a growth of 3% year-on-year in its profit after tax of Rs 114 crore for the fourth quarter of FY12, reported CNBC-TV18 poll.

    • Opto Circuits Sept qtr PAT seen up 40% at Rs 109 cr

      Opto Circuits Sept qtr PAT seen up 40% at Rs 109 cr

      Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Opto Circuits September quarter net sales are expected to go up by 68.3% at Rs 557.6 crore, year-on-year, (YoY) basis.

    • Opto Circuits aims for 30% growth in revenues for FY12

      Opto Circuits aims for 30% growth in revenues for FY12

      V Bhaskar the director finance of Opto Circuits spoke to CNBC-TV18 about the results of the company and what the road ahead looked like.

    • Opto Circuits Mar qtr PAT seen up at Rs 74.8 cr: MOST

      Opto Circuits Mar qtr PAT seen up at Rs 74.8 cr: MOST

      Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Opto Circuits March quarter sales are expected to go up by 62.7% at Rs 544.3 crore, year-on-year, (YoY) basis.

    • Hits & misses in Q3: Rajesh Jain analyses 4 stocks

      Hits & misses in Q3: Rajesh Jain analyses 4 stocks

      Rajesh Jain, Independent Market Strategist

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347